Brief Report

RED CELLS, IRON, AND ERYTHROPOIESIS

2p15-p16.1 microdeletions encompassing and proximal to *BCL11A* are associated with elevated HbF in addition to neurologic impairment

Alister P. W. Funnell,[1] Paolo Prontera,[2] Valentina Ottaviani,[3] Maria Piccione,[4] Antonino Giambona,[5] Aurelio Maggio,[5] Fiorella Ciaffoni,[6] Sandra Stehling-Sun,[1] Manuela Marra,[6] Francesca Masiello,[6] Lilian Varricchio,[7] John A. Stamatoyannopoulos,[1,8] Anna R. Migliaccio,[7,9] and Thalia Papayannopoulou[10]

[1]Department of Genome Sciences, University of Washington, Seattle, WA; [2]Centro di Riferimento Regionale Genetica Medica, Azienda Ospedaliera-Universitaria di Perugia, Perugia, Italy; [3]Genetica Medica, IRCCS "Ospedale Casa Sollievo della Sofferenza," San Giovanni Rotondo, Foggia, Italy; [4]Dipartimento Scienze per la Promozione della Salute e Materno-Infantile "G. D'Alessandro," Università degli Studi di Palermo, Palermo, Italy; [5]Unità Operative Complesse di Ematologia delle Malattie Rare del Sangue e degli Organi Emopoietici, Palermo, Italy; [6]Department of Biologia Cellulare and Neuroscience, Istituto Superiore Sanita, Rome, Italy; [7]Department of Medicine, Mount Sinai School of Medicine, New York, NY; [8]Division of Oncology, Department of Medicine, University of Washington, Seattle, WA; [9]Department of Biomedical Sciences, University of Bologna, Bologna, Italy; and [10]Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

Key Points

- Elevation of HbF in 3 patients heterozygous for distinct 2p15-p16.1 syndrome microdeletions affecting *BCL11A*.
- Identification of novel, putative regulatory elements downstream of *BCL11A* that govern its expression in erythroid cells.

Elevated fetal hemoglobin (HbF) ameliorates the clinical severity of hemoglobinopathies such as β-thalassemia and sickle cell anemia. Currently, the only curative approach for individuals under chronic transfusion/chelation support therapy is allogeneic stem cell transplantation. However, recent analyses of heritable variations in HbF levels have provided a new therapeutic target for HbF reactivation: the transcriptional repressor BCL11A. Erythroid-specific BCL11A abrogation is now actively being sought as a therapeutic avenue, but the specific impact of such disruption in humans remains to be determined. Although single nucleotide polymorphisms in *BCL11A* erythroid regulatory elements have been reported, coding mutations are scarcer. It is thus of great interest that patients have recently been described with microdeletions encompassing *BCL11A*. These patients display neurodevelopmental abnormalities, but whether they show increased HbF has not been reported. We have examined the hematological phenotype, HbF levels, and erythroid *BCL11A* expression in 3 such patients. Haploinsufficiency of *BCL11A* induces only partial developmental γ-globin silencing. Of greater interest is that a patient with a downstream deletion exhibits reduced *BCL11A* expression and increased HbF. Novel erythroid-specific regulatory elements in this region may be required for normal erythroid *BCL11A* expression, whereas loss of separate elements in the developing brain may explain the neurological phenotype. (*Blood*. 2015;126(1):89-93)

Introduction

Chromosome 2p15-p16.1 microdeletions constitute a contiguous gene deletion syndrome characterized by shared phenotypic traits including intellectual disability, growth retardation, and distinct dysmorphisms. To date, 11 microdeletions of discrete lengths have been described, each associated with overlapping subsets of phenotypic features.[1] These deletions collectively encompass approximately 17 protein-coding genes and are accordingly associated with a complex spectrum of physical and mental traits. The smallest microdeletion yet has recently been reported to solely contain the *BCL11A* gene and is associated with hypotonia, mild intellectual delay, speech disorder, and gross motor impairments.[1]

BCL11A is a transcription factor that is highly expressed in the brain, B-lymphocytes, and adult erythroid lineage. It has emerged from several genome-wide association studies as a negative modulator of fetal hemoglobin expression.[2-4] Indeed, *BCL11A* knockout

disrupts developmental silencing of human fetal γ-globin in transgenic mice.[5] Moreover, BCL11A knockdown in primary human erythroid cells results in increased fetal hemoglobin (HbF),[6] whereas conditional knockout in adult sickle cell disease transgenic mice leads to reactivation of γ-globin and amelioration of symptoms.[7] Erythroid-specific abrogation of BCL11A has thus been pursued as an attractive therapeutic for β-hemoglobinopathies.[8] Although HbF-associated single-nucleotide polymorphisms (SNPs) have been shown to disrupt an erythroid enhancer in the second intron of *BCL11A*, until recently, coding *BCL11A* mutations had not been reported.[9-11] Here we have investigated the hematopoietic parameters of 3 patients with distinct de novo, heterozygous deletions encompassing, or proximal to, *BCL11A*. All display modestly reduced *BCL11A* expression and considerable HbF elevation. In one patient, a downstream deletion that leaves the *BCL11A* coding

---

gene intact results in reduced *BCL11A* transcripts in erythroblasts, alluding to the existence of novel, erythroid regulatory elements within this region.

Methods

See the supplemental Data, available on the *Blood* Web site.

Results and discussion

The 3 patients herein have been described previously.[12,13] The first is a 15-year-old female with a 3.5-Mb deletion downstream of *BCL11A* (Figure 1A).[13] The second and third are an 8-year-old female and 7-year-old male with 642-kb and 2.5-Mb deletions, respectively, covering the entire *BCL11A* gene (Figure 1A).[12] Although their neurological and physical traits have been extensively characterized, their hematopoietic profiles have not been previously assessed.

We first determined the extent to which these heterozygous deletions influence *BCL11A* expression in erythroblasts derived from the 3 patients. In all cases, *BCL11A* transcripts were significantly reduced by approximately twofold relative to parental expression (Figure 1B). We also specifically analyzed the abundance of different *BCL11A* messenger RNA (mRNA) isoforms, and found that those implicated in γ-globin repression (*BCL11A-XL* and *BCL11A-L*)[5,6] were significantly downregulated in the patients' erythroblasts, whereas short transcript variants (*BCL11A-S*) were not (Figure 1B). Expression of *KLF1* and *GATA1*, erythroid transcription factors that regulate globin expression, was unaltered (data not shown).

Complete blood counts revealed that hematological parameters were largely normal in the 3 individuals (supplemental Table 1). The third patient displayed mildly reduced hematocrit and increased variability in red blood cell size at 5 months of age. These findings were recapitulated in a follow-up count at 7 years of age. This patient also exhibited modest lymphocytosis at this age. BCL11A is highly expressed in B cells and has been implicated in human B-lymphopoiesis.[7,14] It should be noted, however, that the first 2 patients showed normal lymphocyte levels, suggesting that these hypomorphic *BCL11A* mutations have minimal impact on B-cell numbers.

We next assayed relative amounts of hemoglobin isoforms by high-performance liquid chromatography (HPLC). All 3 patients had markedly elevated fetal γ-globin compared with their unaffected parents (Figure 1C; supplemental Figure 1A). This was reflected both as a fraction of total fetal plus adult β-like globin as well as α-globin (supplemental Figure 1B,C). HPLC analysis of hemoglobin tetramers determined the patients' HbF levels to be 7.3%, 4.8%, and 6.2%, respectively, compared with that of their parents (0.5%, 0.7% and 0.2%, and 0.2% and 0.6%) (Figure 1C). Quantification of individual globin chains revealed that fetal γ-globin represented 11.5%, 8.2%, and 10.0% of total β-like globin in the 3 patients compared with parental levels of 1.5%, 1.9% and 1.3%, and 1.9% and 2.0% (supplemental Figure 1A). In all individuals, a balanced ratio of β-like globin to α-globin was sustained (supplemental Figure 1D).

These results demonstrate that *BCL11A* haploinsufficiency has an appreciable effect on HbF expression. This mirrors findings of the master erythroid regulator KLF1, an upstream activator of *BCL11A*.[15,16] In the short time since a nonsense mutation in KLF1 was initially linked to hereditary persistence of fetal hemoglobin,[15] a raft of additional mutations in the locus have been described resulting from focused sequencing efforts,[17-20] culminating in the recent discovery of a KLF1-null individual.[21] Thus far, *BCL11A* coding mutations have not been frequently encountered. Given its implicated B-lymphopoietic and neurological roles, it is possible that *BCL11A* mutations with erythroid-restricted consequences (ie, elevated HbF) will largely lie in regulatory elements with erythroid activity (as in Bauer et al[9]).

The approximately twofold downregulation of *BCL11A* mRNA in patients 2 and 3 can likely be attributed to monoalleleic expression arising from *BCL11A* heterozygosity. However, in the first patient, both *BCL11A* alleles are intact (Figure 1A). This raises the possibility that downstream regulatory elements within the deleted region are required for full erythroid expression of *BCL11A*. Inspection of this region revealed several prominent DNase-hypersensitive sites in adult erythroid cells that are cobound by various combinations of key erythroid transcription factors (GATA1, TAL1, KLF1, and NFE2) and are enriched for the active enhancer-associated marker H3K4me1 (Figure 2). These elements represent potential erythroid enhancers, although their functional characterization remains to be determined. It is also plausible that the deletion in patient 1 might result in reduced *BCL11A* expression through alternative molecular mechanisms, such as downstream heterochromatic regions being brought into the vicinity of *BCL11A*.

The extent to which BCL11A need be disrupted to induce clinically protective HbF levels in sickle cell and thalassemic sufferers is unknown. The patients here exhibit approximately 5% to 10% HbF and twofold downregulated *BCL11A* mRNA. In sickle cell sufferers, such HbF levels are associated with reduced major organ failure, but higher amounts (>20%) are required to deter recurrent clinical crises.[22] Further, because of limited availability of tissue samples, we have been unable to ascertain whether the increased HbF in these patients is pancellular or heterocellular. This is an important consideration because pancellular upregulation is predominantly associated with clinical amelioration. Indeed, studies using transgenic, humanized sickle cell mice found that HbF levels of approximately 10% or greater were clinically beneficial when expressed in at least two-thirds of peripheral erythrocytes[23] or higher.[24]

During the revision of this manuscript, an additional 3 patients were described, each with heterozygous 2p15-p16.1 deletions distinct from those reported here. Each of these patients exhibited a similar reduction in *BCL11A* expression to the cases here as well as persistence of fetal hemoglobin and unperturbed lymphocytes. However, the reported patients exhibited markedly higher levels of HbF (16.1-29.7%) than those described here. The reason for this discrepancy is unclear, but may be due to modifiers, genetic or otherwise, that influence ethnic or regional variation in HbF levels.[11]

Last, it is worth noting that several of the genes deleted in the 3 patients are expressed during erythroid differentiation (Figure 1A), and their deletion could thus conceivably contribute to the elevated HbF observed. However, the striking phenotypic similarities of the patients (in terms of both *BCL11A* and HbF levels) might suggest that the HbF modifier effects of these genes, which are variably deleted in different combinations, are minimal.

Taken together, these findings suggest that modest downregulation of erythroid BCL11A expression results in markedly increased HbF, supporting the utility of erythroid-specific disruption of BCL11A as a therapeutic for β-hemoglobinopathies. That these hypomorphic *BCL11A* mutations are associated with a spectrum

Figure 1. Patients with 2p15-16.1 microdeletions display depleted *BCL11A* expression in erythroblasts and markedly increased fetal γ-globin in peripheral blood.
(A) Schematic of the 2p15-16.1 region showing segments that are deleted in the 3 patients. In addition to *BCL11A*, the following deleted genes are expressed at 1 or more stages during erythroid maturation:[25] VRK2, *FANCL, PAPOLG, REL, PUS10, PEX13, KIAA1841, C2orf74, AHSA2, USP34, XPO1, FAM161A, CCT4, COMMD1,* and *B3GNT2*. (B) Real-time reverse transcription-polymerase chain reaction quantification of *BCL11A* mRNA isoforms in erythroblasts expanded in vivo derived from patients (n = 3) and matched parents (n = 5). Shown are total *BCL11A* transcripts, isoforms previously implicated in γ-globin repression (*BCL11A-XL* and *BCL11A-L*) and short variants (*BCL11A-S*). All levels have been normalized to *GAPDH* mRNA. Error bars represent standard deviation and *P* values signify analysis of variation comparison. (C) HPLC determination of hemoglobin tetramer levels for the 3 patients and their parents. HbF peaks are shown in red. Note that HbA_2 ($\alpha_2\delta_2$) levels are relatively constant across all samples (2.3%, 2.6%, and 1.6% for the patients, and 2.2%, 2.8% and 2.6%, 2.4% and 2.2%, respectively, for the parents).

Figure 2. A downstream microdeletion associated with reduced *BCL11A* expression contains several putative erythroid enhancers. The region deleted in patient 1 is shown in red. Shown are DNase sequencing tracks for adult erythroblasts (derived from peripheral blood CD34⁺ cells), other hematopoietic cells in which BCL11A is expressed (B cells) or not expressed (T cells), and the developing fetal brain. Sequencing tracks have been emboldened for clarity. Potential erythroid regulatory elements are highlighted with vertical bars and are bound in human pro-erythroblasts by different combinations of noted erythroid transcription factors (GATA1, TAL1, KLF1, and NFE2) as evidenced by chromatin immunoprecipitation (ChIP) sequencing. These regions are also marked by H3K4me1, typically associated with active enhancer elements. Of note, regions highlighted in pink display erythroid DNase hypersensitivity that is not present in the other hematopoietic cells, suggesting that they are erythroid-specific sites. Regions in gray signify DNase-hypersensitive sites at an alternative *VRK2* promoter and upstream element, which are present in other tissues. The segment in blue indicates a known erythroid enhancer in *BCL11A* intron 2, to which SNPs associated with HbF levels are localized.[9] A second cluster of high HbF-associated SNPs (marked by an asterisk) lies downstream of *BCL11A* but outside the deleted region. The fetal brain exhibits widespread DNase hypersensitivity across the deleted region, which might account for the neurological phenotype of this patient.

of neurodevelopmental defects further emphasizes the need for such abrogation to be erythroid-specific. We suggest that candidate erythroid regulatory elements, such as those described previously[9] and here, should be inspected during routine screening of HbF modifiers, and may represent targets for therapeutic intervention.

Acknowledgments

Authorship

Contribution: A.P.W.F. analyzed data and performed the bioinformatics; P.P., V.O., M.P., A.G., L.V., and A.M. provided important hematologic data; M.M., F.C., L.V., and F.M. performed cell culture and analyzed *BCL11A* mRNA expression levels; S.S.-S. conducted the HPLC analysis; T.P., A.R.M., and J.A.S. oversaw project design; T.P. and A.R.M. conceived the study and contributed equally to this work; and A.P.W.F., A.R.M., and T.P. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Thalia Papayannopoulou, Division of Hematology, Department of Medicine, University of Washington, Box 357710, Health Sciences Building, Room K243, Seattle, WA 98195; e-mail: thalp@uw.edu; and Anna Rita Migliaccio, Department of Medicine, Mount Sinai School of Medicine, One Gustave L Levy Pl, Box #1079, New York, NY 10029; e-mail: annarita.migliaccio@mssm.edu.

References

1. Peter B, Matsushita M, Oda K, Raskind W. De novo microdeletion of BCL11A is associated with severe speech sound disorder. *Am J Med Genet A.* 2014;164A(8):2091-2096.

2. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. *Nat Genet.* 2007;39(10):1197-1199.

3. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. *Proc Natl Acad Sci USA.* 2008;105(33):11869-11874.

4. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. *Proc Natl Acad Sci USA.* 2008;105(5):1620-1625.

5. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. *Nature.* 2009; 460(7259):1093-1097.

6. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. *Science.* 2008;322(5909):1839-1842.

7. Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. *Science.* 2011; 334(6058):993-996.

8. Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. *Nat Med.* 2015;21(3):221-230.

9. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. *Science.* 2013;342(6155):253-257.

10. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. *Nat Genet.* 2010;42(12):1049-1051.

11. Basak A, Hancarova M, Ulirsch JC, et al. BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations [published online ahead of print May 4, 2015]. *J Clin Invest.*

12. Piccione M, Piro E, Serraino F, et al. Interstitial deletion of chromosome 2p15-16.1: report of two patients and critical review of current genotype-phenotype correlation. *Eur J Med Genet.* 2012; 55(4):238-244.

13. Prontera P, Bernardini L, Stangoni G, et al. Deletion 2p15-16.1 syndrome: case report and review. *Am J Med Genet A.* 2011;155A(10): 2473-2478.

14. Liu P, Keller JR, Ortiz M, et al. Bcl11a is essential for normal lymphoid development. *Nat Immunol.* 2003;4(6):525-532.

15. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. *Nat Genet.* 2010;42(9):801-805.

16. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and gamma-to beta-globin gene switching. *Nat Genet.* 2010; 42(9):742-744.

17. Satta S, Perseu L, Moi P, et al. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. *Haematologica.* 2011; 96(5):767-770.

18. Gallienne AE, Dréau HM, Schuh A, Old JM, Henderson S. Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. *Haematologica.* 2012;97(3):340-343.

19. Wang T, He Y, Zhou JY, et al. KLF1 gene mutations in Chinese adults with increased fetal hemoglobin. *Hemoglobin.* 2013;37(5):501-506.

20. Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. *Blood.* 2014;124(5):803-811.

21. Magor GW, Tallack MR, Gillinder KR, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. *Blood.* 2015; 125(15):2405-2417.

22. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? *Blood.* 1984;63(4):921-926.

23. Perumbeti A, Higashimoto T, Urbinati F, et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. *Blood.* 2009;114(6):1174-1185.

24. Blouin MJ, Beauchemin H, Wright A, et al. Genetic correction of sickle cell disease: insights using transgenic mouse models. *Nat Med.* 2000; 6(2):177-182.

25. An X, Schulz VP, Li J, et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. *Blood.* 2014;123(22):3466-3477.